2017
DOI: 10.1038/ncomms14780
|View full text |Cite
|
Sign up to set email alerts
|

Neutrophil stunning by metoprolol reduces infarct size

Abstract: The β1-adrenergic-receptor (ADRB1) antagonist metoprolol reduces infarct size in acute myocardial infarction (AMI) patients. The prevailing view has been that metoprolol acts mainly on cardiomyocytes. Here, we demonstrate that metoprolol reduces reperfusion injury by targeting the haematopoietic compartment. Metoprolol inhibits neutrophil migration in an ADRB1-dependent manner. Metoprolol acts during early phases of neutrophil recruitment by impairing structural and functional rearrangements needed for product… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

5
151
0
6

Year Published

2017
2017
2024
2024

Publication Types

Select...
8
1

Relationship

3
6

Authors

Journals

citations
Cited by 178 publications
(162 citation statements)
references
References 56 publications
5
151
0
6
Order By: Relevance
“…The migration of neutrophils from the blood stream into inflamed tissues is a tightly regulated process essential for the rapid development of an effective immune response against injury and invading pathogens. This phenomenon, extensively studied during physiological responses in healthy tissues , is also a key element in the development of many acute and life‐threatening inflammatory pathologies , such as I/R injury . Several therapeutic strategies have been tested both in preclinical and clinical studies of inflammatory conditions to inhibit neutrophil recruitment and/or functions through the use of natural or synthetic (e.g.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The migration of neutrophils from the blood stream into inflamed tissues is a tightly regulated process essential for the rapid development of an effective immune response against injury and invading pathogens. This phenomenon, extensively studied during physiological responses in healthy tissues , is also a key element in the development of many acute and life‐threatening inflammatory pathologies , such as I/R injury . Several therapeutic strategies have been tested both in preclinical and clinical studies of inflammatory conditions to inhibit neutrophil recruitment and/or functions through the use of natural or synthetic (e.g.…”
Section: Discussionmentioning
confidence: 99%
“…These innate immune cells, whilst vital for host defense against pathogens, are implicated in the pathogenesis of many disorders due to their capacity to release a wide range of proinflammatory mediators , reactive oxygen species (ROS) and destructive proteolytic enzymes. Clear evidence for the involvement of neutrophils in I/R injury has been provided by both preclinical and clinical studies in which neutrophil depletion was protective against further tissue damage . Similarly, blocking neutrophil interaction with blood vessel walls within reperfused areas of ischemic tissues improves disease outcome in patients .…”
Section: Introductionmentioning
confidence: 99%
“…Surprisingly, studies in murine models of myocardial injury have shown that adrenergic signalling directly on leucocytes modulates inflammation. Although different forms of β‐adrenergic receptors are expressed on neutrophils, β1‐AR was found to be critical in early stages of myocardial injury: an antagonist for this receptor impaired the migration of neutrophils towards chemotactic stimuli in vitro and hematopoietic‐specific deficiency in the receptor protected from acute injury during the early stages of infarction . Interestingly, inhibition of this receptor leads to aberrant morphology of intravascular neutrophils and reduced motility, similar to that found upon disruption of platelet‐neutrophil interactions .…”
Section: Adrenergic Signalling During Vascular Inflammationmentioning
confidence: 91%
“…Furthermore, the METOCARD trial showed benefit of periprocedural β‐blocker administration on infarct size and MVO . No significant differences in IMH occurrence ( P =0.36) or IMH extent ( P =0.097) were found between patients with and without intravenous periprocedural β‐blockers in the METOCARD trial.…”
Section: Discussionmentioning
confidence: 90%